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Fluorescence in situ hybridization
Seroconversion
Prophylactic vaccination
Assisted reproductive techniquesBackground: Semen represents a reservoir for human papillomavirus (HPV), rising concern in couples eligible for
assisted reproduction techniques (ART). Humoral immunity against HPV is considered to protect from reinfec-
tion. We investigated the impact of vaccination on virus clearance in a cohort of infertile male patients showing
HPV semen infection.
Methods: 179 out of 619 infertile patients, showingHPV-DNA detection in semen by FISH analysis, were enrolled.
Subjects were split into 91 vaccine-sensitive (VSPs) and 88 nonvaccine-sensitive patients (NVSPs) by INNO-LiPA.
19 VSPs showed vaccine-type speciﬁc seroconvesion at recruitment. All patients underwent speciﬁc counselling.
42 seronegative VSPs were randomly assigned to receive quadrivalent vaccination in 6 months, whilst 49 VSPs,
19 seroconverted and 30 seronegative, served as controls. The prevalence of HPV-DNA semen infection and se-
rology was studied in a follow-up of 24 months.
Results: Compared to seronegative patients, VSP seroconverted at recruitment showed absence of multiple infec-
tions and reduced prevalence of HPV semen infection at 12 (P = 0.039), 18 (P = 0.034) and 24 months (P =
0.034) of follow-up. Vaccinated VSP showed improved healing (P = 0.001 at 6 months and P b 0.001 at 12
months vs seroconverted VSP), achieving clearance in 12 months.
Discussion: Humoral immunity has a major role in healing from HPV infection. Elder ART patients with HPV
semen infection may beneﬁt by the union of both speciﬁc counselling and available prophylactic vaccination.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Human papillomavirus (HPV) is one of the most diffuse sexually-
transmitted diseases, with 60% of sexually active people being infected
with at least one high-risk HPV type during their lifetime (Schiffman
et al., 2007). 90% of these infections are generally cleared by the immune
system within 2 years from primary exposure (Woodman et al., 2007).
However, in the remaining cases, infection persists for a long time causing
lesions that can progress into cancer (Castle et al., 2011). In particular, a
reduced number of HPV types infecting the ano-genital area are actually
oncogenic viruses that lead to cervical carcinoma (Tornesello et al.,
2014), the seventh most common cancer in the world (Forman et al.,
2012) and the second most common cancer among women (Arbyn
et al., 2011). High-risk HPVs are also responsible for other types of cancer
common to both genders. In fact, around 80% of tumours of the anus, 60%
of the vagina, and 40% of vulva and penis are induced by HPV, mainly the
HPV 16 type (Parkin and Bray, 2006). Moreover, nearly 90% of, Andrology and Reproductive
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. This is an open access article underoropharynx, 50% of nasopharynx, and 26% of oral cavity tumours show
positive detection for high risk-HPV types, highlighting the causative
role of this virus in head and neck cancers (Walline et al., 2013).
Current therapies for the treatment of HPV infection of the ano-
genital tract aremainly ablative and devoted to the removal of damaged
HPV-infected lesions, such as warts and squamous intraepithelial le-
sions (Krogh von et al., 2000). However, most patients are not featured
by macroscopic lesions. In particular, a variable percentage (13 to 88%)
of asymptomatic men shows a reservoir for HPV in the penile foreskin
(Giuliano et al., 2010). In this regard, semen represents a sampling site
of high diagnostic value for the assessment of HPV infection in asymp-
tomatic males (Laprise et al., 2014).
A growingnumber of evidence concurred to identify the impairment
of human reproduction as a consequence of HPV infection (Foresta et al.,
2015). In fact, a higher prevalence of HPV infection has been reported in
semen from infertile patients, independently of the presence of risk fac-
tors for HPV (Garolla et al., 2011, 2013a; Cai et al., 2014). Detection of
HPV in semen has also been associated with an impairment of sperm
quality, particularly dealingwith cellmotility (Foresta et al., 2010), rein-
forcing the possible involvement of this virus inmale infertility (Garolla
et al., 2011, 2013b). In this context, a possible role of sperm as a carrierthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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nancy rate and detection of HPV-DNA in spermatozoa (Hermonat
et al., 1997), as well as HPV detection in recurrent miscarriage
(Matovina et al., 2004; Conde-Ferráez et al., 2013). Thus, HPV infection
appears as an emergent problem in couples eligible for assisted repro-
duction techniques (ART) (Garolla et al., 2012). On this basis, healing
from virus infection represents a key prerequisite for accession to
assisted fertilization techniques, but the achievement of natural clear-
ance could not be compatible with ART schedule, in particular for cou-
ples of older age (Foresta et al., 2015; Garolla et al., 2013b; Stoop
et al., 2014).
Prophylactic vaccination relies on the development of humoral im-
mune response to viral capsid proteins. This process is assumed to pre-
vent virus infection of basal epithelial cells, through recognition of viral
surface by speciﬁc neutralizing antibodies (Stanley et al., 2012). More-
over, HPV vaccines offer cross-protection against few speciﬁc non-
vaccine HPV types for individuals without previous infection, with the
quadrivalent vaccine showing some degree of protection against HPV
31, 33, and 45, for persistent infection and CIN2+ disease, and little ev-
idence of cross-protection against HPV 52 and 58 (Malagón et al., 2012).
It is generally accepted that this approach is not effective in treating
existing infections or established HPV-related diseases. However, in
both females and males with HPV-related disease, it has been demon-
strated that vaccination with the quadrivalent HPV vaccine reduces
the risk of subsequent disease even after surgical treatment (Joura
et al., 2012; Swedish et al., 2012), suggesting a possiblemajor role of hu-
moral immunity in the healing process from viral infection. In this re-
gard, we observed that patients featured by HPV detection in semen,
together with natural seroconversion, showed faster semen clearance
compared to non-seroconverted patients. This observation prompted
us to evaluate the effect of seroconversion induced by prophylactic vac-
cination on clearance in males showing HPV-DNA detection in semen.
2. Methods
2.1. Participants
The studywas conducted at the Unit of Andrology and Reproductive
Medicine of the University Hospital of Padova, according to the princi-
ples of the Declaration of Helsinki, and approved by the Institutional
Ethics Committee of the Padua General Hospital by Protocol No. 2336
and subsequent amendments.
619 male patients attending the unit for assisted reproduction from
January 2013 to January 2015 underwent outpatient evaluation and
were consecutively recruited, after acceptance of written informed con-
sent. Inclusion criteria were: diagnosis of male infertility deﬁned as alter-
ation of sperm parameters and/or at least 2 years of unprotected sexual
intercourse without conception with female partners without main geni-
tal diseases (tubal factor, uterine factor, cervical abnormalities, and ovari-
an disorders were excluded). Exclusion criteria were: history of
cryptorchidism, testicular trauma, post-mumps orchitis, prior knowledge
of HPV infection, previous or ongoing vaccination at the time of enrol-
ment. Varicocele and bacterial seminal infections were excluded, respec-
tively, by testicularDoppler ultrasound andmicrobiological spermculture.
Semen analysiswas performed according to theWorldHealthOrgani-
zation (World Health Organization, 2010). The presence of anti-sperm
antibodies by SperMAr test, FISH analysis of whole semen for HPV-DNA,
and genotyping at recruitment by the INNO-LiPA Genotyping Extra
assay on whole semen were performed as previously described (Garolla
et al., 2013a). Multiple infections at recruitment were deﬁned as the de-
tection of ≥2 different HPV types in whole semen by a genotyping assay.
2.2. Anti HPV-Antibodies
The presence and titre of serum anti-HPV IgG were assessed on pe-
ripheral blood samples throughout an overall follow-up period of 24months, at recruitment (t0), 6months (t6), 12months (t12), 18months
(t18) and 24 (months). Patients of the vaccine armwere assessed also at
3, 6 and 9 and months (t3, t6 and t9 respectively).
Total anti-HPV immunoglobulin G (IgG) antibodydetectionwas per-
formed by an enzyme linked immuno-sorbent assay ELISA using a com-
mercial kit supplied by DRG Diagnostic GmbH (Germany). The assay
relies on a micro-well plate coated with virus-like particles derived
from L1 protein of viral types 6, 11, 16 and 18 expressed in Saccharomy-
ces cerevisiae. All the assays were performed with the same lot of the
ELISA kit within its declared shelf-life period. According to
manufacturer's instructions, each sample was diluted 1:100 and
analysed in duplicate. The cut-off value was deﬁned as optical density
at 450 nm (OD) of negative control plus 0.250 and seropositive were
samples having OD higher than the cut-off value. Antibody titre was
assessed, with slightmodiﬁcations, in both clearly-seropositive samples
and in samples showing an OD included in the range: (cut-off value) ±
2 × (standard deviation of negative control). In these cases, sera were
serially diluted (1:10–1:100–1:1000, respectively) and assessed as de-
scribed above. Antibody titre was deﬁned as the lowest dilution
displaying anOD ≤ (cut-off value)+2× (standard deviation of negative
control) (Zhao et al., 2014).
2.3. Deﬁnition of Treatment Arms
Fig. 1 shows the ﬂowdiagramof the study. FISH analysis allowed de-
tection of HPV-DNA in the semen in 179 out of 619 infertile patients
(28.9%), further conﬁrmation by INNO-LiPA genotyping allowed us to
identify the following HPV types: 6, 11, 16, 18, 26, 31, 33, 35, 39, 40,
42, 43, 44, 45, 51, 52, 53, 54, 56, 58, 59, 66, 68, 69, 71, 70, 73, 74, and
82. According to cross-protection provided by quadrivalent vaccine
(Malagón et al., 2012; Draper et al., 2013), we identiﬁed 91 out of 179
patients (50.8%) featured by infection of at least one of the HPV types
6, 11, 16, 18, 31, 33, 45, 52, and 58, which were deﬁned as vaccine-
sensitive patients (VSPs). The remaining 88 patients (49.2%), infected
by at least one of the HPV types 26, 35, 39, 40, 42, 43, 44, 51, 53, 54,
56, 59, 66, 68, 69, 71, 70, 73, 74, and 82were called nonvaccine-sensitive
patients (NVSPs). Nineteen out of 91 VSPs (20.9%) showed seroconver-
sion for vaccine-type HPV at recruitment and were speciﬁcally consid-
ered in the control arm as seroconverted patients. 72 seronegative
VSPs at recruitment were then randomly allocated to the control arm,
as seronegative patients, or to a vaccine arm in a blinded fashion by
third-party true randomization in a 1:1 ratio with a random number
generator. Therefore, 49 men (19 seroconverted and 30 seronegative)
were allocated to the control arm and 42 to the vaccine arm. Regardless
to the assignment to any treatment arm, all HPV-positive patients
underwent speciﬁc counselling as previously described (Garolla et al.,
2014), being advised to have protected intercourse, to avoid smoking,
and to refer to our unit in case of wart development.
The prevalence of HPV-DNA detection by FISH analysis in the semen
of patients from the control arm, the vaccine arm and NVSP, was evalu-
ated throughout an overall follow-up period of 24 months, at recruit-
ment (t0), 6 months (t6), 12 months (t12), 18 months (t18) and 24
(months). Patients of the vaccine arm were assessed also at 3 and 6
months (t3 and t6, respectively), after each vaccine dose administration
and at 9 months (t9).
2.4. HPV Vaccination
HPV vaccination was administered as off-label prescription of the
quadrivalent vaccine Gardasil (Merck Serono S.p.A., Milan, Italy). Vac-
cine was administered as 3 injections over 6 months, the second dose
received 2 months after the ﬁrst dose, and the third dose received 6
months after the ﬁrst dose respectively. The procedure was performed
at the Unit of Hygiene and Public Health of Padova Hospital after accep-
tance of written informed consent. Patients receiving HPV vaccination
were further assessed for the presence of HPV-DNA in whole semen
Fig. 1. Deﬁnition, size and prevalence of multiple infections within the treatment arms of the study cohort. Abbreviations: HPV: human papillomavirus; VSP: vaccine sensitive-patients;
NVSP: nonvaccine-sensitive patients.
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respectively.2.5. Statistical Analysis
Data analysis was performed using SPSS version 13.0 (SPSS Inc.,
Chicago, IL, USA). The results were expressed as means ± standard
error means (SEM). The Levene's test was used to test the homogeneity
of variance among groups prior to data analysis. If homogeneity of var-
iance assumption was violated, Welch test was performed and the re-
spective P value was reported. Differences between two groups were
analysed using Student's t-test. Differences between three or more
groups were analysed using ANOVA and Fisher's least signiﬁcant differ-
ence (LSD) adjustment for multiple comparisons of groups was applied
to the pairwise comparisons of groups. Multivariate logistic regression
was performed to adjust for potential confounders, the ﬁnal model in-
cluded variables signiﬁcant at P b 0.10 on univariate analysis. Propor-
tions and discrete variables were compared using the chi-square test
or Fisher's exact test, when expected cell sizes were smaller than ﬁve.
Statistical signiﬁcance was deﬁned at the P b 0.05 level using 2-sided
tests; highly statistical signiﬁcance was deﬁned for values of P b 0.01.Table 1







Age (years) 38.2 ± 8.1
HPV+ Female partner (N) 174 (39.5%)
Sperm concentration (×106/mL) 35.9 ± 8.4
Total sperm count (×106) 112.5 ± 38.7
Progressive motility (%) 39.3 ± 12.1
Normal morphology (%) 17.4 ± 5.3
Viability (%) 85.1 ± 6.4
Positive SpermMar test (N) 32 (18.0%)
Abbreviations: HPV+: patients with positive detection of HPV-DNA in semen; HPV−: patient
niﬁcance: a = P b 0.05 vs HPV-patients; b = P b 0.05 vs HPV+ seronegative patients.3. Results
3.1. Patient's Characteristics
Clinical characteristics of the 619 male patients eligible for recruit-
ment, further divided into 440 HPV-negative subjects and 179 patients
showing HPV-DNA in whole semen, are summarized on Table 1.
Compared to negative subjects, HPV-positive patients were featured
by higher prevalence of HPV-positive partner (150/179 HPV-positive vs
174/440 HPV-negative, P b 0.001), reduced progressive motility
(22.7 ± 13.4% HPV+ vs 39.3 ± 12.1 HPV−, P = 0.042) and higher
prevalence of positive SperMar test (88/179 HPV+ vs 32/440 HPV−,
P b 0.001). By the use of the anti-HPV IgG ELISA Kit, among 179 infected
patients, we identiﬁed 19 subjects showing natural seroconversion at
recruitment for at least one of the HPV types 6, 11, 16 and 18 (HPV+
seroconverted patients). This sub-population showed further decrease
of progressive motility (15.4 ± 9.5% seroconverted vs 23.1 ± 14.2%
non-seroconverted P = 0.039) and increased prevalence of positive
SperMar test, compared to HPV-positive seronegative patients (18/19
seroconverted vs 70/160 nonseroconverted, P b 0.001).
In the whole group of HPV-positive infertile patients, INNO-LiPA










37.1 ± 7.4 40.3 ± 7.9 39.0 ± 9.1
150 (83.8%)a 17 (89.5%)a 133 (83.1%)a
30.4 ± 13.1 29.9 ± 7.9 33.4 ± 15.2
92.9 ± 40.3 90.7 ± 42.6 93.4 ± 39.8
22.7 ± 13.4a 15.4 ± 9.5a,b 23.1 ± 14.2a
14.9 ± 8.7 14.8 ± 10.0 15.1 ± 8.9
74.9 ± 9.8 75.2 ± 7.7 74.4 ± 10.1
88 (49.2%)a 18 (94.7%)a,b 70 (43.8%)a
s with negative detection of HPV-DNA in semen; SD: standard deviation of the mean. Sig-
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On the other hand, HPV52was detected in 32/179 (17.9%), representing
the most prevalent high risk-type (Schiffman et al., 2009), followed by
HPV18 (12/179; 6.7%) and HPV16 (9/179; 5.02%). Multiple infections
at recruitmentwere detected in 22/179 patients (12.3%, Fig. 1), in agree-
ment with previous reports (Rositch et al., 2012; Álvarez-Argüelles
et al., 2013), with no differential distribution between VSP and NVSP
(13/79 vs 9/88, P = 0.497). In particular, simultaneous detection of
two, three and four HPV types was found in 9/22 patients (40.9%) and
8/22 patients (36.4%) and 5/22 (22.7%) respectively. The most frequent
association was represented by HPV6 and HPV52, detected in 4/22 pa-
tients (18.2%).
After assignment to different arms, no signiﬁcant segregation of
multiple infections was observed between patients of the control arm
and the vaccine arm (7/49 vs 4/42 respectively, P = 0.537). Among
the 19 seroconverted patients of the control arm, nomultiple HPV infec-
tions were observed, whilst 13 out of 72 seronegative VSPs were fea-
tured multiple infections at recruitment, with a difference close to
statistical signiﬁcance (P = 0.0625, Fig. 1).
3.2. Detection of HPV-DNA in Semen and Serology of Patients of the Control
Arm and NVSP
The prevalence of infecting HPV-DNA, detected by FISH analysis, in
the semen of patients of both the control arm and NVSPs throughout
an overall observation of 24 months, is summarized on Table 2.
In general, progressive reduction of theprevalence of HPV-semen in-
fectionwas noticed across the period of observation, with no signiﬁcant
difference between respectively seronegative VSP at recruitment and
NVSP at all time points (respectively P = 0.74 at 6 months; P =
0.82 at 12 months; P = 0.99 at 18 months and P = 0.81 at 24 months).
In VSP of the control arm showing natural seroconversion at recruit-
ment, the prevalence of HPV-semen infection was lower at 12, 18 and
24 months compared to both seronegative VSP (P = 0.034 at 12
months; P = 0.034 at 18 months and P = 0.034 at 24 months respec-
tively) and NVSP (P = 0.034 at 12 months; P = 0.011 at 18 months
and P = 0.034 at 24 months respectively).
The mean percentage of sperm showing positive staining for HPV-
DNA is reported on Table 3. Assuming seronegative VSP as reference,
seroconverted VSPs showed a reduced percentage of HPV positive
sperm cells at recruitment (11.6 ± 3.2% seroconverted VSP vs 22.1 ±
5.6% seronegative VSP, P = 0.026), at 6 months (8.0 ± 1.7%
seroconverted VSP vs 14.5 ± 4.2% seronegative VSP, P = 0.031) and at
12 months of follow-up (3.3 ± 2.1% seroconverted VSP vs 16.1 ± 8.1%
seronegative VSP, P = 0.014). No statistical inference was allowed at
18 and 24 because of incompatible numerosity of data. Anti-HPV IgG
titre in seroconverted patients ranged from 1:58 ± 34 at recruitment
to 1:98 ± 71 at 24 months, with no signiﬁcant difference among time
points. At 12 and 18 months of follow-up we observed incident natural
seroconversion in respectively 1 and 2 patients within the group of
seronegative VSP with an overall development of natural sero-
conversion of 3/30 (10%) patients in a 24 months follow up period.
However, no signiﬁcant difference in terms of anti-HPV IgG titre, was
observed between these patients and seroconverted VSP at recruitment.Table 2






(NVSP vs seronegative VSP)
Seroconver
(N = 19)
t0 30 (100%) 88 (100%) 1 19 (100%)
t6 26 (87%) 79 (90%) 0.74 16 (84%)
t12 22 (73%) 61 (69%) 0.82 8 (42%)
t18 10 (33%) 30 (34%) 0.99 1 (5%)
t24 7 (23%) 17 (19%) 0.61 0 (0%)
Abbreviations: t0: recruitment; t6, t12, t18, t24: 6, 12, 18 and 24months from recruitment respe
bold values = P b 0·05.Contingent seroconversion to HPV-vaccine types in NVSP was
assessed in a subgroup of patients (43 out of 88 NVSPs, Table 3), in
order to identify any non-speciﬁc reactivity of the assay. The highest
non-speciﬁc prevalence of seroconversion in this group of patients
was 3/43 (0.9%).
3.3. Detection of HPV-DNA in Semen and Serology of Patients of the Vaccine
Arm
Theprevalence of HPV-DNAdetection in the semen of patients of the
vaccine arm, throughout an overall follow-up period of 24 months, is
summarized on Table 4. All patients complied vaccination treatment.
The prevalence of HPV-DNA detection in semen from vaccinated pa-
tients underwent a rapid decrease, achieving almost complete abolition
within 12months from recruitment. As shown on Table 4, patients from
this arm showed a signiﬁcantly lower prevalence of HPV-DNAdetection
in semen, at 6 and 12months, than both seronegative VSP (P=0.002 at
6 months and P b 0.001 at 12 months) and seroconverted VSPs (P =
0.001 at 6 months and P b 0.001 at 12 months) of the control arm.
Data are graphically summarized in Fig. 2. Also the percentage of HPV-
infected spermatozoa decreased progressively from 24.5 ± 7.1% at re-
cruitment to 10.2 ± 3.4%·4.8 ± 5.0%·2.3 ± 2.1% and 0% at respectively
3, 6, 9 and 12 months in course of vaccine treatment (Supplemental
Table 1). In addition, all vaccinated patients underwent seroconversion
within 6 months from recruitment, showing higher anti-HPV IgG titre
than sero-converted patients of the control arm (6 months follow-up
1:882 ± 408 vaccine vs 1:66 ± 56 seroconverted control arm P b
0.001; 12 months follow-up 1:795 ± 320 vaccine vs 1:85 ± 56
seroconverted control arm P b 0.001. Supplemental Table 1).
4. Discussion
Recent clinical trials demonstrated the high efﬁcacy of prophylactic
vaccination for genital condyloma and precancerous lesions, such
as cervical and vulvar intraepithelial neoplasia, related to HPV infec-
tion in girls and women (Garland et al., 2007; Brisson et al., 2007;
Paavonen et al., 2009). However, due to main disparities in the
vaccination rate between males and females (Cifu and Davis, 2014),
cost-effectiveness of the use of HPV vaccine inmales is largely under-
investigated. In this study we proof evidence that HPV prophylactic
vaccination in adult males signiﬁcantly improves healing from viral
semen infection.
There is a general consensus that immunobiology of HPV clearance
in course of natural infection mainly relies on cell-mediated immunity
(Stanley, 2006). In this context, the role of natural humoral immunity
is believed to exert minor protective effects through the neutralization
of functional epitopes on the virus surface, mediating internalization
into basal epithelial cells, and preventing the primary entry or re-
entry of virions (Carter et al., 1996). However, this model only partially
explains major epidemiological and serological differences between
genders. In fact, a peak in the prevalence of HPV infection features fe-
males at the age of 20–35 years, approximately at the age of sexual
debut, followed by a progressive decreasewith age. Inmales, the detec-
tion of HPV-DNA in the genital area is observed at a lower prevalencepatients.
ted VSP P value
(Seroconverted VSP vs seronegative VSP)
P value






ctively; VSP: vaccine sensitive patients; NVSP: nonvaccine-sensitive patients. Signiﬁcance:
Table 3
Detection of HPV-positive cells in semen, seroconversion and antibody titre of both patients of the control arm and non-vaccine sensitive patients.
Seronegative VSP (N = 30) NVSP (N = 88) Seroconverted VSP (N = 19)
Time-point % HPV + cells
(mean ± SD)
Seroconverted patients
(gm titre ± SD)
% HPV + cells
(mean ± SD)
Seroconverted patients
(gm titre ± SD)
% HPV + cells
(mean ± SD)
Seroconverted patients
(gm mean titre ± SD)
t0 22.1 ± 5.6 0 27 ± 6.4 2/43
(1:65 ± 58)
11.6 ± 3.2%* 19
(1:58 ± 34n.a.)
t6 14.5 ± 4.2 0 11 ± 7.2 3/43
(1:42 ± 73)
8.0 ± 1.7%* 19
(1:66 ± 56n.a.)
t12 16.1 ± 8.1 1
(1:72)
10 ± 9.3 1/43
(1:126)
3.3 ± 2.1%* 19
(1:85 ± 43n.a.)
t18 8.1 ± 3.8 3
(1:62 ± 37)




t24 4.8 ± 3.4 3
(1:94 ± 21)




Abbreviations: t0: recruitment; t6, t12, t18, t24: 6, 12, 18 and 24 months from recruitment respectively; % HPV+ cells: percentage of HPV-DNA positive-spermatozoa; VSP: vaccine sen-
sitive patients; NVSP: nonvaccine-sensitive patients; gm titre: geometric mean of the antibody titre; SD: standard deviation of the mean.
Signiﬁcance: n.a. = not available; * = P b 0·05 vs seronegative VSP; n.s. = P ≥ 0·05 vs seronegative VSP.
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et al., 2009; Klinglmair et al., 2013). On the other hand, the overall sero-
prevalence among females appears very low until 15 years and then un-
dergoes a progressive increase to 29.3–32.5% until early 30s and
subsequent slight reduction in older ages. In contrast, seroprevalence
in males remains below 3% until the age of 19, undergoing a slight in-
crease to 12.2–13.5% until about 20 to 24 years of age, after which it is
stabilized (Desai et al., 2011;Markowitz et al., 2009). These data suggest
that, despite neutralizing antibodies are not always developed during a
natural viral load, they cannot be considered just as a serologicalmarker
of an ongoing or previous HPV infection, but a key tool involved in the
healingprocess. This is in agreementwith early observations in humans,
showing that HPV-type-speciﬁc IgG antibodies are detectable in serum
during spontaneous regression of warts, presumably resulting from ex-
posure of virions to the immune systemat the time of initial infection, or
due to re-infection during productive phase of the disease (Greer et al.,
1995; Wikström et al., 1995). In our cohort of HPV-positive infertile
men, the seroprevalence toward HPV in the group of VSP is 20.8% (19/
91), a higher value compared to seroprevalence reported for the general
male population (Desai et al., 2011;Markowitz et al., 2009). This is likely
to be ascribable to the widely reported higher percentages of semen in-
fection in infertile subjects compared to fertile controls, as reviewed
(Foresta et al., 2015). It has to be considered that, at enrolment, patients
were counselled for the management of semen infection, posing a
forced condition of limited re-infection probability that favours healingTable 4
Prevalence ofHPV-DNAdetection in semenof seronegative vaccine-sensitive patients (Se-
ronegative VSP), seroconverted vaccine-sensitive patients (Seroconverted VSP) and pa-

















t0 30 (100%) 19 (100%) 42 (100%)
t3 N.P. N.P. 31 (74%)
t6 26 (87%) 16 (84%) 17 (40%)a,c
t9 N.P. N.P. 3 (7%)
t12 22 (73%) 8 (42%)a 0b,d
t18 10 (33%) 1 (5%)a 0
t24 7 (23%) 0 (0%)a 0
Abbreviations: t0: recruitment; t3, t6, t9, t12, t18, t24: 3, 6, 9, 12, 18 and 24 months from
recruitment respectively; N.P.: not performed.
Signiﬁcance: a = P b 0.05 vs seronegative VSP; b = P b 0.001 vs seronegative VSP; c = P b
0.05 vs seroconverted VSP; d = P b 0.001 vs seroconverted VSP.(Garolla et al., 2014). In this context, seroconverted patients at recruit-
ment showed a higher prevalence of anti-sperm antibodies compared
to the seronegative ones, reﬂecting an active ongoing immune response
in the genito-urinary tract toward virus particles bound on sperm sur-
face (Garolla et al., 2013b). As a counterpart, seroconverted patients
showed a further improved clearance and a virtual absence of multiple
infections compared to seronegative, even if with low levels of signiﬁ-
cance probably due to the low sample size of the cohort, reinforcing a
role for humoral immunity in healing from viral infection and re-
infection.
In agreement with this hypothesis, we evaluated virus clearance in
patients undergoing prophylactic treatment with quadrivalent vaccine.
In order to exclude any confounding effect of viral re-infection with
nonvaccine-sensitive HPV types, we speciﬁcally selected patients infect-
ed by vaccine-sensitive HPV types (Malagón et al., 2012) in the vaccine
arm. Surprisingly, the prevalence of HPV infection underwent a strong
reduction at each time point compared to the control arm, achieving al-
most abrogation within 9 to 12 months. Moreover, within 6 months
after the ﬁrst administration, seroconversion was detected in the
whole vaccine arm, displaying an average antibody titre 10 folds higher
than patients developingnatural seroconversion, coherentlywith previ-
ous reports (Hillman et al., 2012). In this regard, curative effects of neu-
tralizing antibodies against recombinant self-assembled virus-like
particles were early suggested in animal models (Ghim et al., 2000;
Suzich et al., 1995). These studies showed that protection from oral ca-
nine papillomavirus infection was provided by passive transfer of hy-
perimmune IgG collected from regressor animals, supporting a role for
systemic humoral immunity in healing from oral papillomas (Ghim
et al., 2000; Suzich et al., 1995). Furthermore recent data frommamma-
lianmodels, assessingpassive immunizationwith sera fromanimals im-
munized with the commercially available vaccines, showed that anti-
HPV antibodies are protective even at low titres (Day et al., 2010).
This evidence is of particular importance, accounting for the efﬁciency
of cross-protecting anti-HPV antibodies toward non-vaccine types, de-
spite they are generally under-represented compared to vaccine type
ones. There is a general debate about the role of HPV on sperm quality
(Foresta et al., 2015; Golob et al., 2014). In this regard, a main limitation
of the present study is the lack of the investigation on the impact of HPV
on sperm quality over the 2 years study. We previously reported that
the strict relationship among HPV semen infection, detection of anti-
sperm antibodies and impaired sperm motility relies on an actual local
immune response toward HPV particles bound to sperm surface
(Garolla et al., 2013b, 2014). Accordingly, healing from viral infection
was accompanied by a progressive improvement of both the prevalence
of anti-sperm antibodies and sperm motility. If vaccination boosts the
clearance of HPV by arousing local immune response in the genito-
urinary tract, a temporary increase of the anti-sperm antibodies and
consistent reduction of sperm motility should be expected, followed
Fig. 2. Prevalence of HPV-DNA detection in semen of patients from the vaccine arm (dotted line) and from the control arm. Control arm is further split into patient seronegative at recruit-
ment (thick continuous line) and showing seroconversion at recruitment (thin continuous line). Signiﬁcance: * = P b 0.05 vs seronegative patients of the control arm. †= P ≤ 0.001 vs
seroconverted patients of the control arm.
1492 C. Foresta et al. / EBioMedicine 2 (2015) 1487–1493by a global improvement of sperm parameters at the achievement of
clearance. However further studieswill add further insight on this issue.
Our results assume a particular relevance in the light of the actual
lack of an efﬁcient therapy, able to eradicate HPV infection (Rosales
and Rosales, 2014). In addition, we recently highlighted HPV infec-
tion to be an emergent problem in couples eligible for assisted repro-
duction techniques (Foresta et al., 2015; Garolla et al., 2013a), in
particular when it is not possible to delay fertility seeking due to
the age of the female partner. Persistent infection in these cases is
not always compatible with repeated 6-months counselling-cycles
to allow any spontaneous clearance. Even if the cost-effectiveness
analysis of fertility improvement in HPV vaccinated male is a manda-
tory step, our ancillary results suggest a potential beneﬁt of male
vaccination to overcome fertility problems related to persistent
HPV infections. In this regard, further investigations are in progress
to assess whether HPV clearance in males is relevant for the protec-
tion against HPV-related diseases of the female partner.
Persistence of HPV infection depends on both viral and host factors
(Veldhuijzen et al., 2010). HPV-type concordance studies (Reiter et al.,
2010) are coherent in suggesting penile skin to be more resistant to
HPV infection than the cervical epithelium and a considerable contribu-
tion of local humoral immunity to this evidence is suggested (Garolla
et al., 2013b; Marais et al., 2006). However, speciﬁc studies in this
ﬁeld are missing and the lack of a thorough proﬁling of immune milieu
in semen represents a major drawback of the present study. In this re-
gard, data in the HIV model documented mucosal HIV-1-speciﬁc IgA,
systemic HIV-1-speciﬁc CD4 IFNα-producing cells and HIV-1-speciﬁc
CD8 T lymphocytes in exposed seronegative men, resulting in immune
activation in lymphocytes puriﬁed from seminal ﬂuid but not in periph-
eral blood lymphocytes (Lo Caputo et al., 2003). Similarly, serum HIV-
speciﬁc IgA was observed in exposed seronegative women (Mazzoli
et al., 1999), but not detected in exposed seronegative men, supporting
a role of mucosal immunity as a more efﬁcient limiting factor for viral
infection in males than in females. Thus, in the HPV model, the evalua-
tion of local mucosal and cellular immunity in men could provide a
comprehensive explanation of our ﬁndings about HPV clearance kinetic
in both seropositive and seronegative subjects.
In conclusion, our data suggest that HPV prophylactic vaccination is
effective in reducing mean clearance time in patients featured by HPV
semen infection. This evidence may have a breakthrough impact on
the clinical approach to patients with long-lasting HPV semen infection,
and in particular for those infertile patients eligible for ART.Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ebiom.2015.09.005.
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